These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 17891008

  • 21. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I.
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [Abstract] [Full Text] [Related]

  • 22. Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events.
    Battaglia Parodi M, Di Bartolo E, Brue C, Cappello E, Furino C, Giuffrida S, Imparato M, Reibaldi M.
    Eur J Ophthalmol; 2018 Jan; 28(1):58-62. PubMed ID: 29077191
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, Azarmina M, Dehghan MH, Moradian S.
    BMC Ophthalmol; 2007 Jun 07; 7():10. PubMed ID: 17555600
    [Abstract] [Full Text] [Related]

  • 25. Pegaptanib for choroidal neovascularization in treatment-naïve exudative age-related macular degeneration.
    Ehlers JP, Fintak DR, Gupta OP, Regillo CD, Fineman MS, Ho AC.
    Ophthalmic Surg Lasers Imaging; 2007 Jun 07; 38(5):371-7. PubMed ID: 17955841
    [Abstract] [Full Text] [Related]

  • 26. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN.
    Am J Ophthalmol; 2006 Jul 07; 142(1):1-9. PubMed ID: 16815245
    [Abstract] [Full Text] [Related]

  • 27. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed.
    Farah SE.
    Ophthalmic Surg Lasers Imaging; 2008 Jul 07; 39(4):294-8. PubMed ID: 18717434
    [Abstract] [Full Text] [Related]

  • 28. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R, Gabric N.
    Ophthalmology; 2007 Jun 07; 114(6):1179-85. PubMed ID: 17544776
    [Abstract] [Full Text] [Related]

  • 29. Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration.
    Calvo-González C, Reche-Frutos J, Donate-López J, García-Feijoó J, Leila M, Fernández-Pérez C, Garcia-Sánchez J.
    Br J Ophthalmol; 2008 Jan 07; 92(1):74-5. PubMed ID: 18156376
    [Abstract] [Full Text] [Related]

  • 30. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.
    Retina; 2011 Apr 07; 31(4):645-53. PubMed ID: 21358363
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L, Ruiz-Moreno JM, Gómez-Ulla F, Fernández M, Montero J.
    Retina; 2009 Apr 07; 29(10):1444-9. PubMed ID: 19730163
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.
    Augustin AJ, Puls S, Offermann I.
    Retina; 2007 Feb 07; 27(2):133-40. PubMed ID: 17290193
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.
    Ophthalmology; 2009 Sep 07; 116(9):1740-7. PubMed ID: 19643484
    [Abstract] [Full Text] [Related]

  • 36. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization.
    Eandi CM, Ober MD, Freund KB, Slakter JS, Yannuzzi LA.
    Retina; 2007 Sep 07; 27(7):825-31. PubMed ID: 17891004
    [Abstract] [Full Text] [Related]

  • 37. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.
    Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE.
    Am J Ophthalmol; 2009 May 07; 147(5):831-7. PubMed ID: 19217019
    [Abstract] [Full Text] [Related]

  • 38. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
    Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML.
    Retina; 2007 May 07; 27(4):439-44. PubMed ID: 17420695
    [Abstract] [Full Text] [Related]

  • 39. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G.
    Retina; 2006 May 07; 26(5):495-511. PubMed ID: 16770255
    [Abstract] [Full Text] [Related]

  • 40. Pegaptanib combined with intravitreal injection of moxifloxacin as treatment of wet macular degeneration.
    Bennett MD, Yee W, Bryan JS.
    Retina; 2008 May 07; 28(7):976-80. PubMed ID: 18698300
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.